Galcanezumab (Norwegian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Galcanezumab" in Norwegian language version.

refsWebsite

Global rank Norwegian rank

447^th place

2,058^th place

2web.archive.org

1^st place

1^st place

3,257^th place

3,082^nd place

195^th place

381^st place

68^th place

84^th place

220^th place

689^th place

49^th place

132^nd place

ama-assn.org

"Statement on a Nonproprietary Name Adopted by the USAN Council - Galcanezumab", American Medical Association.

cnbc.com

«US FDA approves Lilly migraine drug at a price that is the same as its rivals». CNBC. CNBC. Reuters. 28. september 2018. Besøkt 29. september 2018.

europa.eu

ema.europa.eu

«Emgality EPAR». Besøkt 28.04.2020.

fda.gov

fda.gov

(pressemelding) https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-episodic-cluster-headache-reduces-frequency-attacks. Manglende eller tom |tittel= (hjelp)
«Drug Trials Snapshots: Emgality». U.S. Food and Drug Administration (FDA). Arkivert fra originalen 7. desember 2019. Besøkt 7. desember 2019.

accessdata.fda.gov

«Drug Approval Package: Emgality (galcanezumab-gnlm)». U.S. Food and Drug Administration (FDA). Arkivert fra originalen 7. desember 2019. Besøkt 7. desember 2019.

reuters.com

Erman, Michael. «FDA approves Lilly's migraine drug as first ever cluster headache treatment». Reuters. Besøkt 28. april 2020.

web.archive.org

«Drug Approval Package: Emgality (galcanezumab-gnlm)». U.S. Food and Drug Administration (FDA). Arkivert fra originalen 7. desember 2019. Besøkt 7. desember 2019.
«Drug Trials Snapshots: Emgality». U.S. Food and Drug Administration (FDA). Arkivert fra originalen 7. desember 2019. Besøkt 7. desember 2019.

who.int

«International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114» (PDF). WHO Drug Information. 29 (4). 2015 – via World Health Organization.